melatonin has been researched along with Parkinsonian Disorders in 27 studies
Parkinsonian Disorders: A group of disorders which feature impaired motor control characterized by bradykinesia, MUSCLE RIGIDITY; TREMOR; and postural instability. Parkinsonian diseases are generally divided into primary parkinsonism (see PARKINSON DISEASE), secondary parkinsonism (see PARKINSON DISEASE, SECONDARY) and inherited forms. These conditions are associated with dysfunction of dopaminergic or closely related motor integration neuronal pathways in the BASAL GANGLIA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Melatonin has been shown to be highly effective in reducing oxidative damage in the central nervous system; this efficacy derives from its ability to directly scavenge a number of free radicals and to function as an indirect antioxidant." | 2.40 | Melatonin as a pharmacological agent against neuronal loss in experimental models of Huntington's disease, Alzheimer's disease and parkinsonism. ( Cabrera, J; Manchester, LC; Mayo, JC; Reiter, RJ; Sainz, RM; Tan, DX, 1999) |
| "Melatonin was administered (20 mg/kg) intraperitoneally to Group-M and Group-P + M twice a day for five days." | 1.72 | Role of melatonin in TLR4-mediated inflammatory pathway in the MTPT-induced mouse model. ( Agar, A; Aytac, G; Ozkan, A; Tanriover, G; Yildirim, S, 2022) |
| "Melatonin treatment attenuated the decrease in tyrosine hydroxylase in the striatum and abolished it in the substantia nigra." | 1.43 | Chronic low-dose melatonin treatment maintains nigrostriatal integrity in an intrastriatal rotenone model of Parkinson's disease. ( Carriere, CH; Kang, NH; Niles, LP, 2016) |
| "Melatonin treatment significantly decreased COX, PGE2 and caspase-3 activity, increased Bcl-2 and had no effect on NF-κB levels in experimental PD." | 1.40 | Mechanism of the beneficial effect of melatonin in experimental Parkinson's disease. ( Agar, A; Aslan, M; Dilmac, S; Gemici, B; Kaya, Y; Ogut, E; Ozkan, A; Ozsoy, O; Tanriover, G; Yildirim, FB, 2014) |
| "Melatonin is a neurohormone secreted by the pineal gland, which has several important physiological functions." | 1.40 | Neuroprotective and antidepressant-like effects of melatonin in a rotenone-induced Parkinson's disease model in rats. ( Andreatini, R; Barbiero, JK; Bassani, TB; Boschen, SL; da Cunha, C; Gradowski, RW; Lima, MM; Santiago, RM; Vital, MA; Zaminelli, T, 2014) |
| "Melatonin is a natural antioxidant and free radical scavenger that has been shown to effectively reduce cellular oxidative stress and protect mitochondrial functions in vitro." | 1.37 | Melatonin protects against neurobehavioral and mitochondrial deficits in a chronic mouse model of Parkinson's disease. ( Lau, YS; Patki, G, 2011) |
| "Melatonin has been reported to be neuroprotective in the 6-hydroxydopamine (6-OHDA) and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) models of PD." | 1.36 | Melatonin treatment potentiates neurodegeneration in a rat rotenone Parkinson's disease model. ( Cannon, JR; Greenamyre, JT; Tapias, V, 2010) |
| "Melatonin treatment significantly attenuated both the L-DOPA and MPTP-induced increases in the levels of striatal 6-OHDA, and protected against striatal DA depletion caused by the neurotoxin." | 1.35 | Melatonin inhibits 6-hydroxydopamine production in the brain to protect against experimental parkinsonism in rodents. ( Borah, A; Mohanakumar, KP, 2009) |
| "Melatonin treatment restored the rotenone-induced decrease in GSH level and changes in antioxidant enzyme (SOD and catalase) activities in the SN." | 1.34 | Melatonin protects against rotenone-induced oxidative stress in a hemiparkinsonian rat model. ( Mohanakumar, KP; Saravanan, KS; Sindhu, KM, 2007) |
| "Melatonin was initially dissolved in dimethyl sulfoxide (DMSO), diluted to 16 microg/ml and then provided in the drinking water for 4 weeks." | 1.31 | Chronic administration of pharmacological levels of melatonin does not ameliorate the MPTP-induced degeneration of the nigrostriatal pathway. ( Morgan, WW; Nelson, JF, 2001) |
| " We found that the antioxidant melatonin (500 microg/kg bw) prevents cell death as well as the damage induced by chronic administration of MPTP measured as number of nigral cells, tyrosine hydroxylase levels, and several ultra-structural features." | 1.31 | Protective effect of melatonin in a chronic experimental model of Parkinson's disease. ( Antolín, I; del Brío, Mde L; Herrera, F; Martín, V; Mayo, JC; Rodríguez, C; Sainz, RM, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (3.70) | 18.2507 |
| 2000's | 13 (48.15) | 29.6817 |
| 2010's | 12 (44.44) | 24.3611 |
| 2020's | 1 (3.70) | 2.80 |
| Authors | Studies |
|---|---|
| Yildirim, S | 1 |
| Ozkan, A | 2 |
| Aytac, G | 1 |
| Agar, A | 2 |
| Tanriover, G | 2 |
| Jagota, A | 1 |
| Mattam, U | 1 |
| Yurchenko, EA | 1 |
| Menchinskaya, ES | 1 |
| Pislyagin, EA | 1 |
| Trinh, PTH | 1 |
| Ivanets, EV | 1 |
| Smetanina, OF | 1 |
| Yurchenko, AN | 1 |
| Singhal, NK | 2 |
| Chauhan, AK | 1 |
| Jain, SK | 2 |
| Shanker, R | 1 |
| Singh, C | 1 |
| Singh, MP | 2 |
| Zaitone, SA | 1 |
| Hammad, LN | 1 |
| Farag, NE | 1 |
| Yildirim, FB | 1 |
| Ozsoy, O | 1 |
| Kaya, Y | 1 |
| Ogut, E | 1 |
| Gemici, B | 1 |
| Dilmac, S | 1 |
| Aslan, M | 1 |
| Bassani, TB | 1 |
| Gradowski, RW | 1 |
| Zaminelli, T | 1 |
| Barbiero, JK | 1 |
| Santiago, RM | 1 |
| Boschen, SL | 1 |
| da Cunha, C | 1 |
| Lima, MM | 1 |
| Andreatini, R | 1 |
| Vital, MA | 1 |
| Naskar, A | 1 |
| Prabhakar, V | 1 |
| Singh, R | 1 |
| Dutta, D | 1 |
| Mohanakumar, KP | 3 |
| Carriere, CH | 1 |
| Kang, NH | 1 |
| Niles, LP | 1 |
| Talanov, SA | 2 |
| Sahach, VF | 2 |
| Tapias, V | 2 |
| Escames, G | 1 |
| López, LC | 1 |
| López, A | 1 |
| Camacho, E | 1 |
| Carrión, MD | 1 |
| Entrena, A | 1 |
| Gallo, MA | 1 |
| Espinosa, A | 1 |
| Acuña-Castroviejo, D | 1 |
| Cannon, JR | 1 |
| Greenamyre, JT | 1 |
| Borah, A | 1 |
| Timoshchuk, SV | 1 |
| Rudyk, OV | 1 |
| Arushanian, EB | 1 |
| Patki, G | 1 |
| Lau, YS | 1 |
| Srivastava, G | 1 |
| Agrawal, S | 1 |
| Coulom, H | 1 |
| Birman, S | 1 |
| Willis, GL | 2 |
| Robertson, AD | 2 |
| Singh, S | 1 |
| Ahmed, R | 1 |
| Sagar, RK | 1 |
| Krishana, B | 1 |
| Saravanan, KS | 1 |
| Sindhu, KM | 1 |
| Lin, CH | 1 |
| Huang, JY | 1 |
| Ching, CH | 1 |
| Chuang, JI | 1 |
| Reiter, RJ | 1 |
| Cabrera, J | 1 |
| Sainz, RM | 2 |
| Mayo, JC | 2 |
| Manchester, LC | 1 |
| Tan, DX | 1 |
| Lin, AM | 1 |
| Morgan, WW | 1 |
| Nelson, JF | 1 |
| Antolín, I | 1 |
| del Brío, Mde L | 1 |
| Herrera, F | 1 |
| Martín, V | 1 |
| Rodríguez, C | 1 |
3 reviews available for melatonin and Parkinsonian Disorders
| Article | Year |
|---|---|
[A hormonal drug melatonin in the treatment of cognitive function disorders in parkinsonism].
Topics: Cognition Disorders; Corpus Striatum; Dementia; Humans; Melatonin; Neuroprotective Agents; Nootropic | 2010 |
Melatonin as a neuroprotective agent in the rodent models of Parkinson's disease: is it all set to irrefutable clinical translation?
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Humans; Melatonin; Neuroprotective Agents; Pa | 2012 |
Melatonin as a pharmacological agent against neuronal loss in experimental models of Huntington's disease, Alzheimer's disease and parkinsonism.
Topics: Alzheimer Disease; Animals; Cell Death; Drug Evaluation, Preclinical; Free Radical Scavengers; Free | 1999 |
1 trial available for melatonin and Parkinsonian Disorders
| Article | Year |
|---|---|
Recovery from experimental Parkinson's disease in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine hydrochloride treated marmoset with the melatonin analogue ML-23.
Topics: 5-Methoxytryptamine; Animals; Behavior, Animal; Callithrix; Cross-Over Studies; Eating; Male; Melato | 2005 |
23 other studies available for melatonin and Parkinsonian Disorders
| Article | Year |
|---|---|
Role of melatonin in TLR4-mediated inflammatory pathway in the MTPT-induced mouse model.
Topics: Animals; Male; Melatonin; Mice; Mice, Inbred C57BL; Neuroinflammatory Diseases; Parkinsonian Disorde | 2022 |
Daily chronomics of proteomic profile in aging and rotenone-induced Parkinson's disease model in male Wistar rat and its modulation by melatonin.
Topics: Age Factors; Aging; Animals; Biomarkers; Brain; Circadian Rhythm; Disease Models, Animal; Electropho | 2017 |
Neuroprotective Activity of Some Marine Fungal Metabolites in the 6-Hydroxydopamin- and Paraquat-Induced Parkinson's Disease Models.
Topics: Alkaloids; Animals; Antioxidants; Antiparkinson Agents; Aquatic Organisms; Aspergillus; Biological P | 2018 |
Silymarin- and melatonin-mediated changes in the expression of selected genes in pesticides-induced Parkinsonism.
Topics: Animals; Antioxidants; Apoptosis; Cell Cycle; Disease Models, Animal; Gene Expression Regulation; In | 2013 |
Antioxidant potential of melatonin enhances the response to L-dopa in 1-methyl 4-phenyl 1,2,3,6-tetrahydropyridine-parkinsonian mice.
Topics: Animals; Antioxidants; Antiparkinson Agents; Basal Ganglia; Behavior, Animal; Carbidopa; Catalase; D | 2013 |
Mechanism of the beneficial effect of melatonin in experimental Parkinson's disease.
Topics: Animals; Antioxidants; Dopaminergic Neurons; Male; Melatonin; Motor Activity; Oxidopamine; Parkinson | 2014 |
Neuroprotective and antidepressant-like effects of melatonin in a rotenone-induced Parkinson's disease model in rats.
Topics: Animals; Antidepressive Agents; Corpus Striatum; Dopamine; Male; Melatonin; Motor Activity; Neuropro | 2014 |
Melatonin enhances L-DOPA therapeutic effects, helps to reduce its dose, and protects dopaminergic neurons in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Dopaminergic Neurons; D | 2015 |
Chronic low-dose melatonin treatment maintains nigrostriatal integrity in an intrastriatal rotenone model of Parkinson's disease.
Topics: Animals; Antioxidants; Corpus Striatum; Disease Models, Animal; Immunohistochemistry; Male; Melatoni | 2016 |
[Antioxidants prevent experimental hemiparkinsonism in rats].
Topics: Animals; Antioxidants; Behavior, Animal; Chromans; Disease Models, Animal; Dopamine; Male; Melatonin | 2008 |
Melatonin and its brain metabolite N(1)-acetyl-5-methoxykynuramine prevent mitochondrial nitric oxide synthase induction in parkinsonian mice.
Topics: Animals; Calcium; Corpus Striatum; Cytosol; Electron Transport Complex I; Enzyme Induction; Kynurami | 2009 |
Melatonin treatment potentiates neurodegeneration in a rat rotenone Parkinson's disease model.
Topics: Animals; Body Weight; Cell Count; Cell Death; Corpus Striatum; Disease Models, Animal; Dopamine; Mel | 2010 |
Melatonin inhibits 6-hydroxydopamine production in the brain to protect against experimental parkinsonism in rodents.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Ascorbic Acid; Brain; Central Nervous System | 2009 |
[An increased sensitivity of the mitochondrial permeability transition pore to calcium in the heart of rats with chronic deficiency of nigrostriatal dopamine].
Topics: Animals; Calcium; Chronic Disease; Corpus Striatum; Dopamine; Dose-Response Relationship, Drug; Hear | 2009 |
Melatonin protects against neurobehavioral and mitochondrial deficits in a chronic mouse model of Parkinson's disease.
Topics: Adenosine Triphosphate; Animals; Antiparkinson Agents; Behavior, Animal; Corpus Striatum; Free Radic | 2011 |
Chronic exposure to rotenone models sporadic Parkinson's disease in Drosophila melanogaster.
Topics: Animals; Antioxidants; Apoptosis; Brain; Cell Count; Dopamine; Dopamine Agonists; Drosophila melanog | 2004 |
Recovery of experimental Parkinson's disease with the melatonin analogues ML-23 and S-20928 in a chronic, bilateral 6-OHDA model: a new mechanism involving antagonism of the melatonin receptor.
Topics: 5-Methoxytryptamine; Animals; Male; Melatonin; Naphthalenes; Oxidopamine; Parkinsonian Disorders; Ra | 2004 |
Neuroprotection of the nigrostriatal dopaminergic neurons by melatonin in hemiparkinsonium rat.
Topics: Animals; Dopamine; Female; Melatonin; Neurons; Neuroprotective Agents; Oxidopamine; Parkinsonian Dis | 2006 |
Melatonin protects against rotenone-induced oxidative stress in a hemiparkinsonian rat model.
Topics: Animals; Catalase; Glutathione; Hydroxyl Radical; Male; Melatonin; Oxidative Stress; Parkinsonian Di | 2007 |
Melatonin reduces the neuronal loss, downregulation of dopamine transporter, and upregulation of D2 receptor in rotenone-induced parkinsonian rats.
Topics: Animals; Cell Count; Disease Models, Animal; Dopamine Plasma Membrane Transport Proteins; Down-Regul | 2008 |
Coexistence of zinc and iron augmented oxidative injuries in the nigrostriatal dopaminergic system of SD rats.
Topics: Anesthesia; Animals; Brain; Corpus Striatum; Deferoxamine; Dopamine; Drug Interactions; Glutathione; | 2001 |
Chronic administration of pharmacological levels of melatonin does not ameliorate the MPTP-induced degeneration of the nigrostriatal pathway.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Catecholamine | 2001 |
Protective effect of melatonin in a chronic experimental model of Parkinson's disease.
Topics: Animals; Axons; Cell Death; Chronic Disease; Disease Models, Animal; DNA Fragmentation; Dose-Respons | 2002 |